22,589 Shares in Prestige Consumer Healthcare Inc. $PBH Purchased by Jupiter Topco LLC

Key Points

• Jupiter Topco LLC acquired 22,589 shares of Prestige Consumer Healthcare during the second quarter, valued at approximately $1.07 million. Institutional investors collectively own 99.95% of PBH.
• Prestige Consumer Healthcare reported quarterly EPS of $0.98, exceeding estimates of $0.89, while revenue rose 6.5% year over year to $265.71 million.
• PBH shares opened at $52.17, well below the analyst consensus price target of $70.75. Analyst sentiment is mixed, resulting in a consensus rating of Hold.

Jupiter Topco LLC acquired a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) during the second quarter, according to its most recent filing with the SEC. The firm acquired 22,589 shares of the company's stock, valued at approximately $1,068,000.

Other hedge funds also recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Prestige Consumer Healthcare during the 2nd quarter worth about $370,187,000. Rice Hall James & Associates LLC acquired a new stake in shares of Prestige Consumer Healthcare in the 2nd quarter valued at approximately $32,602,000. The Manufacturers Life Insurance Company bought a new position in Prestige Consumer Healthcare during the 2nd quarter worth approximately $31,135,000. Norges Bank bought a new position in Prestige Consumer Healthcare during the 4th quarter worth approximately $36,954,000. Finally, Bank of New York Mellon Corp acquired a new position in Prestige Consumer Healthcare during the second quarter valued at approximately $15,376,000. Institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Stock Down 0.7%

Prestige Consumer Healthcare stock opened at $52.17 on Friday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99. The company's 50-day moving average is $50.76 and its 200-day moving average is $54.14. The firm has a market capitalization of $2.47 billion, a PE ratio of 14.61, a P/E/G ratio of 1.64 and a beta of 0.33. Prestige Consumer Healthcare Inc. has a fifty-two week low of $42.62 and a fifty-two week high of $71.07.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The business had revenue of $265.71 million during the quarter, compared to the consensus estimate of $253.02 million. During the same period last year, the business posted $0.90 EPS. Prestige Consumer Healthcare's revenue was up 6.5% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.56 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on PBH shares. Oppenheimer downgraded shares of Prestige Consumer Healthcare from an "outperform" rating to a "market perform" rating in a research note on Thursday, May 14th. Zacks Research raised Prestige Consumer Healthcare from a "strong sell" rating to a "hold" rating in a research note on Monday, August 10th. Weiss Ratings downgraded shares of Prestige Consumer Healthcare from a "hold (c-)" rating to a "sell (d+)" rating in a report on Thursday, June 25th. Finally, Canaccord Genuity Group cut their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a "buy" rating on the stock in a research report on Friday, May 15th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $70.75.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.

Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source